Sherpa News

PCI Pharma Services Completes Acquisition of Sherpa Clinical Packaging

Philadelphia, USAOctober 2, 2018 — Leading global biopharmaceutical outsourcing services provider PCI Pharma Services (PCI) has announced the completion of its acquisition of Sherpa Clinical Packaging (Sherpa). Located in San Diego, Sherpa is a recognized provider of clinical trial materials management services and is known for its high quality, flexibility, and speed-to-market in support of investigational studies conducted around the world. Sherpa’s packaging, labeling, distribution, temperature controlled storage and returns services are highly complementary to PCI and adding this key geography strengthens PCI’s ability to support existing and new customers. PCI now has manufacturing and packaging facilities in 8 key locations across three continents and an extensive depot network to service its customers’ global needs.

Read More

Sherpa Clinical Packaging Rolls Out CAD Kit Design and Manufacturing Services

San Diego, Calif. August 29, 2018 — Sherpa Clinical Packaging, a leading provider of clinical materials management services, has launched Computer-Assisted Design (CAD) services to prototype and manufacture custom packaging specifically suited to clinical trials.

“We are always looking for new ways to provide our customers with the utmost flexibility in designing and managing their clinical supplies,” says Mark Paiz, President of Sherpa. “Our latest CAD kit design service can rapidly prototype kits in a matter of hours, and produce the materials in a matter of days, instead of weeks so that our customers can meet their aggressive “first patient in” milestones.”

Read More

PCI Pharma Services to Acquire Sherpa Clinical Packaging

SAN DIEGOSept. 11, 2018 /PRNewswire/ — Leading clinical services provider Sherpa Clinical Packaging (Sherpa) has announced an agreement to be acquired by PCI Pharma Services (PCI). Sherpa, headquartered in San Diego, CA, provides clinical trial material management services for clinical studies phases I-IV, including packaging, labeling, distribution, storage and returns and destruction services. Sherpa’s state-of-the art facilities employ the latest cold chain technologies that include handling products requiring labeling and kitting at frozen and refrigerated conditions.

Read More

Sherpa Clinical Packaging and De:terminence Announce Initiative to Help Rare Disease Patients Climb Mountains

Sacramento and San Diego, CA, August 21, 2018 — Sherpa Clinical Packaging and De:terminence are pleased to announce a joint fundraiser to raise $50,000 to help rare disease patients conquer physically grueling challenges. All proceeds raised will be used to fund scholarships, adaptive equipment, and customized training to prepare rare disease patients to climb mountains, participate in triathlons and marathons across the US.

“Being told that you have a disease for which there is no cure is crushing,” says Sean Baumstark, founder of De:terminence and Friedreich’s Ataxia patient. “I founded De:terminence to remind other rare disease patients that life is still worth living right now, not only if a cure is found. De:terminence provides specialized practical and emotional support rare disease patients need to accomplish amazing physical feats.”

Read More

Sherpa Clinical Packaging Rolls Out API Sampling & Storage Services

San Diego, Calif. February 27, 2018 — Sherpa Clinical Packaging, a leading provider of clinical materials management services, announced new Active Pharmaceutical Ingredient (API) sampling and storage services today.

Sherpa’s ISO 8 API sampling room has been designed and validated to manage a broad range of APIs, including high potency APIs (HPAPI). Their recent GMP facility expansion provides additional temperature-controlled storage space, part of which will be dedicated to API storage.

Read More

Sherpa Clinical Packaging to Convene Expert Panel on Brexit’s Impact on Clinical Trials in the European Union

Panel to Focus on Brexit’s Implications for the US Pharmaceutical Industry

San Diego, Calif. July 26, 2017— The UK’s decision to exit the European Union has far-reaching implications for US pharmaceutical companies trying to break into the EU drug market. The lack of regulatory clarity during this negotiation period between the UK and the EU makes it difficult to plan and execute long-term clinical strategies in the EU. Sherpa Clinical Packaging will be convening a panel of experts to advise on future milestones that pharmaceutical companies should carefully consider as they solidify their plans to bring potential life-saving therapies to the EU clinical research market.

Read More

Sherpa Clinical Packaging Expands Operational Capacity

SAN DIEGO, March 30, 2017 /PRNewswire/ —  Sherpa Clinical Packaging continues to invest in growth and infrastructure with its latest facility addition. The facility expansion will support continued growth in Sherpa’s packaging, labeling, and distribution services, especially as it relates to later stage projects and global studies. The new building will house four packaging suites, a class 100,000 cleanroom, and various temperature-controlled storage areas including expansive 2-8°C and -20°C rooms, and a Controlled Room Temperature warehouse. The new cGMP facility consists of 24,000 ft2 and is adjacent to Sherpa’s existing 38,000 ft2 headquarters.

Read More

Sherpa Clinical Packaging moves blistering capabilities in-house

SAN DIEGO, Sept. 13, 2016 /PRNewswire/ –Sherpa Clinical Packaging, a leading provider of clinical materials management services is now offering in-house blister packaging capabilities available at its facility in San Diego, CA. The new capability will help Sherpa better serve the increasing demands for primary clinical packaging services.

Read More

Sherpa Clinical Packaging announces completion of move to a new GMP clinical Packaging and Distribution facility in San Diego

SAN DIEGO, Feb. 22, 2016 /PRNewswire/ — Sherpa, a clinical packaging company strategically located in the heart of the San Diego biotech community, demonstrates commitment to its clinical trial materials management business by investing in infrastructure. The new state-of-the-art facility is 37,500 ft2 and offers enhanced capabilities and a strict cold chain management infrastructure. The expansion was needed to support the company’s increased demand for Phase 2 and Phase 3 clinical studies and is a result of continued growth serving new and existing clients.

Read More